Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

BSCE > Biochemistry > Flashcards

Biochemistry Flashcards

1
Q

Prothrombin Time (PT) / INR

A

Measures coagulation along extrinsic as well as common pathway
INR is a corrected lab value of PT - measures responsiveness to warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Causes of increased PT/INR

A

Deficiency ofextrinsic or common path, intravascular coagulation, anti-phospholipid syndrome (assoc with SLE), vitamin K deficiency, liver disease, warfarin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

APTT (PTT)

A

Measures coagulation along intrinsic path and common path

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Components of intrinsic pathway

A

12, 11, 9, 8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Disorders causing increased PTT

A

Intrinsic pathway or common probs, von willebrand disease, anti phosph, vitamin k def, liver disease, hemophilia, warfarin (but PT is better), unfractioned heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Activated protein C

A

Requires protein S cofactor, inhibits intrinsic path

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Antithrombin III

A

Inhibitor of clotting cascade. Inhibits thrombin, and factors 2 + 7 = 9 10 11 12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

t-PA (tissue plasminogen activator)

A

Fibronoylytic agent - ie breakdown of blood clots. Bind fibrin and converts plasminogen to plasmin. Plasmin breaks fibrin down into degradation product, ie D diners.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Primary hémostases

A

Goal: form a weak platelet plug, preventing extent of hemorrhage. Secondary hémostases further seals plus.
Steps:
Vasoconstriction, platelet adhesion, platelet activation, platelet aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Endothelin 1 (ET-1)

A

Mediates vasoconstriction in the first step of primary hemostasis. Extremely potent vasoconstrictor peptide synthesised by injured epithelium.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Von willebrand factor

A

Synthesized by megakaryocytes, stored in alpha granules of platelets, and in weibel-palade bodies of endothelium.
Mediates adhesion by binding both GPIb and exposed collagen on subendothelium.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Von willebrand disease

A

Genetic deficiency of vWF, resulting in bleeding diatheses bc decreased ability for platelet adhesion (VwF binds GPib and exposed collagen)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bernard Soulier syndrome

A

Deficiency of GPIb. Mutations inhibiting expression, impairing binding of platelets to vWF on endothelial cells. Have thrombocytopenia and enlarged platelets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Endothelial cell products

A

Synthesized PGI2/prostacyclin and nitric oxide (NO), potent inhibitors of aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Products of activated platelets

A

Secrete TXA2 - potent inducer of activation and aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Aspirin

A

Inhibitor of COXI, thus decreases TXA2 synthesis (inhibiting platelet aggregation). Low dose aspirin important because it also blocks formation of PGI2 by endothelial cells which we need, but at low doses, endothelial cells can regenerate fast enough for this not to matter.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Thrombasthenia of Glanzman and Niegli

A

Genetic deficiency of GPIIB/IIIa - decreased ability to facilitate platelet aggregation, bleeding disorder.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Pancreatitis indicators

A

(Right) Upper quadrant pain radiating to the back, elevated serum amylase and lipase
So could be an obstruction in ampulla of vater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Biliary colic

A

Could arise from obstruction of cystic duct - intermittent pain in épigastrium or R upper quadrant, radiates to scapula. Gallblader may become inflamed resulting in cholecystitis.
Obstruction of common bile duct presents with symptoms similar to obstruction of cystic duct

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Diverticulitis

A

Inflammation of one or more diverticula.- could lead to microperforations of affected colon. Sigmoid colon most commonly affected. Left lower quadrant pain, change in bowel habits, nausea, vomiting, constipation, diarrhoea.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Acromegaly

A

Excess GH in adults - typically caused by pituitary adenoma. Large tongue, deep voice, coarsening faces, frontal bossing, impaired glucose tolerance (insulin resistance)
Increased serum IGF-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Allopurinol

A

Inhibits Xanthine Oxidase. Prevents formation of Uris acid in purine metabolism. Not the treatment of choice in acute gout flares - used more for chronic gout treatment. For acute flares use NSADs ie indomethacin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Classic Galactosemia

A

AR. Galactose-1-phosphate uridyltransferase deficiency (couples G1P with UTP to form UDP galactose)
Can result in cataracts. Poor feeding, vomiting, diarrhoea followed by hepatomegaly, jaundice, renal problems, neurological symptoms. Accumulation of G1P and galactose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Non-classical galactosemia

A

Galactokinase deficiency. Galactosemia and galactosuria. G1p is NOT formed. Galacticol accumulates if galactose (lactose) in diet –> cataracts. Rarer than classical and less severe.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Alkaptonuria

A

AR defect in tyrosine metabolism. Deficiency of homogentisic acid oxidase, increased homogentisic acid levels in blood and urine. Homogentisate in urine is oxidised to alkapton on standing (black brown colour)
Deposition of dark blue/gray pigment throughout body (ochronosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

MODY

A

AD form of non-insulin dependent diabetes - age of onset less than 25 yo.
MODY type 2 - diabetes related to mutations in glucokinase. Inability to phosphorylase glucose to G6P during glycolysis. –> resultant higher threshold for glucose-stimulus insulin secretion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Type VII Glycogen Storage Disease (Tarui disease)

A

Defect in PFK-1, responsible for phosphorylation of F6P to F16BP. Exercise-induced muscle cramps and weakness, hepatomegaly, ketosis, hyperlipidemia, mildly elevated transaminases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Cori Cycle

A

Process of waste removal from muscle to liver. Pyruvate to lactate in the muscle by LDH to regenerate NAD+ to allow glycolysis to proceed. Lactate enters bloodstream to liver. LDH in liver catalyses reverse reaction. Pyruvate ultimately converted back to glucose via gluconeogenesis.

29
Q

Increased anion gap metabolic acidosis

A

MUDPILES - methanol, uraemia, diabetic ketoacidosis, propylene glycol, iron or isoniazid, lactic acidosis, ethylene glycol, salicylate toxicity

30
Q

Salicylate toxicity

A

Uncoupling agents.- allowing ETC to dissipate
Initial raise in CO2 from ETC stimulates central respiratory centre - increase in respiration –> respiratory alkalosis. Acid metabolites then build up in blood causing metabolic acidosis. Mixed.

31
Q

Glycogen storage disease type II (pompe disease)

A

AR.Deficiency in lysosomal acid maltase - presents early infancy with hypotonia, poor feeding, failure to thrive, cardiac insufficiency caused by hypertrophic cardiomyopathy. hepatomegaly may be present but only due to cardiac insufficiency. Macroglossial
Accumulation of glycogen in lysosomes and cytoplasm, resulting in tissue destruction.

32
Q

SAM

A

primary methyl donor, helps methylate DNA. After donation, is hydrolysed to homocysteine and adenosine, Regeneration of methionine from homocysteine requires folate and B12.

33
Q

How is excess nitrogen breakdown from skeletal muscle transported to liver for excretion

A

NH3 produced in protein catabolism is toxic. NH3 is transferred from glutamate to pyruvate in a transamination reaction, forming alanine and alpha ketoglutarate. Alanine exits muscle, travels in blood to the liver, where it is transaminated in reverse, regenerating pyruvate and glutamate. Pyruvate is used in gluconeogenesis, and glutamate provides one NH3 to form urea.

34
Q

Homocystinuria

A

AR. Incl in most newborn screens. Defect in cystathione B synthase, elevated levels of homocysteine. Homocysteine is converted to cystathione via cystathione B synthase or it can regenerate methionine.
Subluxations of lens, arterial disease, binds CT.

35
Q

COP II and COP I transport

A

COP II is anterograde - from rough ER to cis-golgi. And from cis golgi to trans golgi. COP I is retrograde

36
Q

Cri du Chat

A

Partial deletion of short arm of chromosome 5. (5p). Most cases are de novo mutation. Cry like meowing, microcephaly, facial abnormalities, intellectual disabilities, poor muscle tone, ventricular septal defect.

37
Q

Orotic Aciduria

A

Macrocytic anemia, inadequate pyrimidine synthesis. Orotic acid normally converted to UMP by UMP synthase. Megaloblastic anemia refractory to folate and vitamin B12 supplementation.

38
Q

OTC deficiency

A

X linked R. Ornithine transcarbamoylase deficiency. Most common urea cycle disorder. Prevents conversion of ornithine and carbamoyl phosphate to citrulline, preventing elmination of ammonia. Excess carbamoyl phosphate converted to orotic acid, leading to elevate levels.
Orotic aciduria also have elevated orotic acid levels, but here we see hyperammonemia (differential)

39
Q

Alpha amantin

A

Inhibit RNA Pol II - RNA pol II transcribes mRN.

40
Q

Kwashiorkor

A

Insufficient protein intake. Capillary oncotic pressure decreases, tissue edema. Swollen belly due to ascites (fluid in peritoneal cavity), dilated bowel loops, enlarged, fatty liver. Fatty liver due to decreased apolipoprotein synthesis - fats trapped in liver that would normally be exported.

41
Q

Osteogenesis Imperfecta Type I

A

AD. Normal quality collagen in insufficient quantities. Multiple bone fractures, scoliosis, joint laxity, blue sclera, hearing loss.

42
Q

Azidothymidine (AZT)

A

Antiviral nucleoside. Treatment of HIV in combination with other anti-virals - hinders REPLICATION ability of HIV by lack of 3’ OH incorporation.

43
Q

Didanosine (DD)

A

Antiviral nucleoside. No 3’OH - HIV, hinders ability to replication. Reverse transcriptase has 100-300x affinity for dd and AZT than host cell, but there are still side effects. Gamma pol in mitochondria can be affected

44
Q

Tenofovir

A

Anti-viral nucleotide. No 3;OH on pentose sugar – termination. Used in HIV

45
Q

Acyclovir

A

Anti-viral nucleoside. Deoxygunaosine analogue. Thymidine kinase adds 1P, host kinase adds another. Only affected cells have thymidine kinase and viral DNA pol - chain termination. Treat herpes and varicella zoster,

46
Q

Cytosine Arabinoside (AraC)

A

Anti-cancer. AraC triphosphate in cells, bad stereochemistry – termination. Used in leukaemia (acute myeloid lymphoma) - only for blood cancer because rapidly degen in blood

47
Q

Adenosine arabinoside (AraA)

A

Anti-cancer. Has 3’OH, but planar configuration. Used for relapsed childhood acute lymphoblastic anemia.

48
Q

Decitabine

A

DNA hypomethylating agent. Incorporated in DNA - C5 replaced by N, so can’t methylate. Causes hypomethylation – transcription of tumour suppressor.
Used in myelodysplastic syndrome and AML

49
Q

5-azacytidine

A

RNA hypomthylating agent (cytidine analogue)

Similar mech as decitbine?

50
Q

Leukocyte differential count, in order normal ranges

A

(Neutrophils Like Making Everything Better)

  1. Neutrophils 54-62%
  2. Lymphocytes - 25-33%
  3. Monocytes - 3-7%
  4. Eosinophils 1-3%
  5. Basophils 0.- 0.75%
51
Q

Neutrophil

A

(Normal count, 54-62%) - Acut inflammatory response cell, increased in bactrial infectinos. Specific granules leukocytes alkaline pohsphatase, colllagnas, lysozyme, lactoferrin. Lysosomes incl proteinases, acid phosphatase, myeloperoxidase, and B-glucuronidase.

52
Q

Monocytes

A

3-7% , differentiate into macrophages in tissues. Monocyte - in the blood.

53
Q

Eosinophils

A

Major Basic protein defends parasitic infections. Phagocytose antigen-antibody complexes.

54
Q

Basophils

A

Mediate allergic reaction, densely basophilic granules. Contain heparin (anticoagulant) and histamine (vasodilator).

55
Q

Mast Cell

A

Allergic reaction in local tissues. Same precursor as basophils but not same cell type.

56
Q

Fetal erythropoeisis locations

A

Yolk Sac (3-8), Liver (6 wks to birth), Spleen (10-28 wks), bone marrow (18 wks to adult)

57
Q

Anticoagulants

A

Heparin , enhances activity of antithrombin.
Antithrombin targets thrombin and factor Xa.
Protein C cleaves Va and VIIIa
Plasminogen, activated to plasmin via tPA, plasmin then initiates fibrinolysis - cleave fibrin mesh, destruction of coagulation factors.

58
Q

Forms of microcytic, hypochromic anemia

A

Iron deficiency (low iron, increased TIBC, decreased ferritin)
Alpha thalassemia (hydrops fetalis if 4 allele deletion (form HbBarts, gamma tetramers))
B thalassemia: minor: increased HbA2
major: homo, target cells and anisopoikilocytosis, increased HbF
Lead poisoning: inhibits ferrocheletase and ALA dehydratase
Sideroblastic anemia: x-linked ALA synthase defect. Genetic, acquired, vitamin B6 def etc.

59
Q

Folate deficiency

A

Megaloblastic anemia – impaired DNA synth, maturation of precursor cells
Malnutrition, malabsorption
Findings: increased homocystein, normal methylmalonic acid. No neuro symptoms

60
Q

Vitamin B12 deficiency

A

Megaloblastic anemia. INsuff intake, malabsoprtion (crohns, ileal resec), pernicious anemia
Findings: INcreased homocysteine, increasd methylmalonic acid
Neurologic: degeneration bc B12 involved in fatty acid paths and myelin synth.

61
Q

Orotic Aciduria

A

Deficiency of UMP synthase (orotic acid to UMP)AR, megaloblastic anemi refractory to folate and B12. No hyperammonemia (veruss ornithine transcarbamylase deficiency, inceased orotic acid with hyperammonemia)

62
Q

Hereditary Spherocytosis

A

Extravascular hemolysis - defect in proteins interacting with RBC membrane skeleton and pm (ankyrin, band 3, prot 4.2, spectrin) - premature removal by spleen, small round RBCs decreased surface area. Splenomegaly.

63
Q

Acute Intermittent Porphyria (AIP)

A

Porphobilinogen Deaminase def. (PBC to HMB). Porphobilinogen, gam-ALA, and coporphobilinogen(urine) accumulate
Painful abdomen, Port win coloured urine, polyneuropathy, psych disturbance, precipitated by drugs (cyp p-450, induces ALA synthase 1 liver, increases production of ALA etc increased buildup)
Treat with glucose and heme - inhibit ala synthase

64
Q

Porphyria Cutanea Tarda

A 
Uroporphyrinogen Decarboxylase def.
Uroporphyrin accumulates (tea-coloured urine) - blistering cutaneous photosensitivity. Most common porphyria
AD
65
Q

Actinomycin D

A

Intercalates DNA. Childhood tumours, wilms tumor. Adver effects: myelosuppression.

66
Q

Etoposide

A

Inhibits Topoisomese II – increased DNA degradation. Clinical use for solid tumors, leukemias, lymphomas.

67
Q

Topotecan

A

inhibits Topoisomerase I. Prevents DNA unwinding an replication. Colon cancer, ovarian and small cell lung cancers.

68
Q

Hydroxyurea

A

Inhibits ribonuclotide reductase, decreased Dna Synthsis (S-phase specific), clinical use in melanoma, CML, sickle cell disease (increases HbF).

69
Q

Menopause findings

A

Decreased estrogen, so high increased in FSH, increased LH (no surge), Increased GnRH
Hot flashes, Atrophy of vag, osteoporosis, coronary artery disease, sleep disturbances.

BSCE (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions